IVIG can produce measurable changes within hours for some blood disorders, but takes weeks or even months to show its full effect in neurological and autoimmune conditions. The timeline depends almost entirely on the condition being treated and the mechanism IVIG needs to engage. In immune thrombocytopenia, for instance, platelet counts start climbing within the first day, while chronic nerve diseases may require several treatment cycles before patients notice meaningful improvement. Understanding these different timelines helps set realistic expectations and prevents premature conclusions about whether the treatment is working.
What Happens in Your Blood After an Infusion
When IVIG is infused into a vein, IgG levels in the bloodstream spike immediately. One study documented serum IgG concentrations jumping from about 10 g/L before infusion to roughly 23 g/L by the time the infusion ended.1PubMed. Pharmacokinetics of a new 10% intravenous immunoglobulin in patients receiving replacement therapy for primary immunodeficiency That initial surge then drops quickly over the next few days as the IgG redistributes from the bloodstream into tissues and lymphatic fluid.2PubMed Central. Subcutaneous immunoglobulin: opportunities and outlook After that rapid early decline, the remaining IgG is broken down more slowly, with a half-life that typically falls between three and five weeks, though this varies considerably from person to person.3PubMed. Pharmacokinetics and Pharmacodynamics of Intravenous Immunoglobulin G Maintenance Therapy in Chronic Immune-mediated Neuropathies
This pharmacokinetic pattern matters because it sets the outer boundary of how fast IVIG can work. The drug is in your system within minutes, but the downstream biological effects, whether that means blocking platelet destruction, calming an overactive immune response, or modulating inflammation in nerve tissue, each unfold on their own schedule.
Immune Thrombocytopenia: Hours to Days
IVIG works faster in immune thrombocytopenia (ITP) than in almost any other condition. In ITP, antibodies attack and destroy platelets, leaving the blood unable to clot properly. IVIG is thought to overwhelm the receptors on immune cells that normally clear those antibody-tagged platelets, giving platelet counts a chance to recover.
A randomized trial in children with ITP found that by eight hours after completing IVIG treatment, more than half had platelet counts above 20,000/µL, up from severely low starting levels.4Blood Advances. IVMP+IVIG raises platelet counts faster than IVIG alone: results of a randomized, blinded trial in childhood ITP By 24 hours, nearly 90 percent of children in the IVIG-alone group had crossed that threshold, and by 72 hours the average count had climbed to about 143,000/µL. A separate analysis of 116 children with ITP found the average rate of platelet rise was about 1.3 thousand per microliter per hour, though this ranged widely from essentially zero to over 4 thousand per hour.5Journal of Pediatric Hematology/Oncology. Rate of Rise of Platelet Count After IVIG for Pediatric Immune Thrombocytopenia
The platelet bump from IVIG is dramatic but temporary. In the randomized trial, the average count had fallen back to around 40,000/µL by day 21.4Blood Advances. IVMP+IVIG raises platelet counts faster than IVIG alone: results of a randomized, blinded trial in childhood ITP This is why IVIG in ITP is typically used as a bridge to stop active bleeding or before surgery rather than as a long-term fix.
Kawasaki Disease: Fever Resolution Within One to Two Days
Kawasaki disease causes inflammation of blood vessels, primarily in young children, and the main treatment goal is preventing damage to the coronary arteries. IVIG is given as a single large dose, and fever is the primary marker clinicians track to gauge whether it’s working.
Most children who respond to IVIG see their fever break within 24 to 36 hours after the infusion ends. However, persistent fever in that window is a strong signal that the treatment may not be sufficient. Children who still had fever at 24 to 36 hours post-IVIG had roughly 30 times the odds of being classified as IVIG-resistant compared to those whose fevers resolved.6PubMed Central. Patterns of Fever in Children After Primary Treatment for Kawasaki Disease Fevers occurring even earlier, within the first 12 hours after IVIG, were associated with a higher likelihood of coronary artery abnormalities.7Circulation. Abstract O.38: Fever Patterns in KD Patients after Treatment with IVIG
Roughly 10 to 20 percent of Kawasaki patients are IVIG-resistant, meaning their fever persists or recurs despite the standard dose. A large multicenter Korean study identified elevated markers of inflammation, including higher neutrophil counts and C-reactive protein, as predictors of resistance.8PubMed Central. Factors Predicting Resistance to Intravenous Immunoglobulin Treatment and Coronary Artery Lesion in Patients with Kawasaki Disease: Analysis of the Korean Nationwide Multicenter Survey from 2012 to 2014 More recent work has pointed to additional blood markers that may help identify at-risk children before and after treatment, allowing clinicians to intervene more quickly with second-line therapies.9PubMed Central. Evaluation of laboratory predictors for intravenous immunoglobulin resistance and coronary artery aneurysm in Kawasaki Disease before and after therapy
Guillain-Barré Syndrome: Weeks to Months, and Timing Matters
Guillain-Barré syndrome (GBS) is an acute condition in which the immune system attacks the peripheral nerves, causing weakness that can progress to paralysis. Unlike ITP, where the effect of IVIG shows up overnight, recovery in GBS unfolds over weeks or months. IVIG speeds up this recovery but does not produce an overnight reversal.
Practice guidelines confirm that IVIG treatment hastens recovery from GBS, and it is considered equivalent to plasma exchange as a first-line therapy.10PubMed. Practice parameter: immunotherapy for Guillain-Barré syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology One key finding is that the increase in IgG levels two weeks after treatment predicts how well a patient will do. Patients whose IgG rose the most after IVIG were about four times more likely to walk unaided at six months than patients with the smallest rise, suggesting that how much IgG the body retains after treatment directly affects the speed of nerve recovery.11PubMed Central. IVIG Treatment and Prognosis in Guillain–Barré Syndrome
When IVIG is started also makes a substantial difference. A 2024 study found that shorter time from symptom onset to IVIG treatment was independently associated with better disability scores and shorter time to walking unaided, and the benefit of IVIG dropped off sharply when given more than two weeks after symptoms began.12PubMed. Timing of intravenous immunoglobulin treatment and outcome in Guillain-Barré syndrome: Is time nerve? The message is clear: in GBS, getting IVIG started early matters enormously, even though you won’t see its full effects for weeks.
Chronic Inflammatory Demyelinating Polyneuropathy: Three to Six Weeks for Initial Response
CIDP is the chronic counterpart to GBS, a long-term condition in which immune attacks on nerve coatings cause progressive weakness and numbness. Because the damage accumulates slowly, the response to IVIG is measured differently than in acute conditions.
In a clinical trial of IVIG for CIDP, about half of the patients who responded showed measurable improvement in disability scores by week three, while the other half needed a second infusion cycle and didn’t improve until week six.13JAMA Neurology. Timing and Course of Clinical Response to Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Those who improved by week three tended to have more severe disability at baseline, possibly because they had more room for detectable improvement. Among those who responded, maximal improvement continued to build during maintenance therapy for up to 24 weeks.
A larger randomized trial tested three different IVIG maintenance doses and found that after the initial high-dose loading, more than half of all patients improved within the first few weeks. The median time to reaching meaningful improvement ranged from 22 to 26 days across the dose groups, and by week six, roughly 87 percent of all enrolled patients had improved.14Brain. Randomized trial of three IVIg doses for treating chronic inflammatory demyelinating polyneuropathy For CIDP, then, the practical answer is that you should expect to give IVIG at least three to six weeks before deciding whether it’s working.
Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome: Days
These are severe drug reactions in which the skin essentially blisters and peels off, a medical emergency with significant mortality risk. IVIG is used in these situations to block the immune signaling that drives skin cell death, and the response timeline is among the fastest for any dermatologic condition.
In a multicenter retrospective study of 48 patients with toxic epidermal necrolysis, IVIG stopped the progression of skin and mucosal detachment within an average of about two days. Ninety percent of patients responded, and complete healing of skin and mucous membranes occurred within an average of 15 days.15JAMA Dermatology. Treatment of Toxic Epidermal Necrolysis With High-Dose Intravenous Immunoglobulins: Multicenter Retrospective Analysis of 48 Consecutive Cases Findings in children were similar: skin detachment halted in about two days on average, with complete re-epithelialization in about eight days.16Journal of the American Academy of Dermatology. Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children A study focused on Stevens-Johnson syndrome, the less severe end of the same spectrum, reported all patients responding within a mean of two days, with total skin healing by about eight days.17Dermatology. Effect of High-Dose Intravenous Immunoglobulin Therapy in Stevens-Johnson Syndrome: A Retrospective, Multicenter Study
Multifocal Motor Neuropathy and Other Nerve Conditions
Multifocal motor neuropathy (MMN) is a condition in which the immune system attacks motor nerves, causing progressive weakness, usually in the hands and arms. IVIG is one of the few treatments that works, and patients typically need ongoing infusions to maintain their strength.
Studies of nerve function in MMN and CIDP patients have shown that IVIG produces detectable changes in nerve excitability within days of an infusion course, well before any structural nerve repair could occur. Researchers noted that this short delay rules out remyelination or nerve regeneration as the immediate mechanism, pointing instead to a direct effect on nerve membrane function.18PubMed. Nerve excitability changes after intravenous immunoglobulin infusions in multifocal motor neuropathy and chronic inflammatory demyelinating neuropathy In clinical practice, however, the strength improvements that patients actually notice tend to build over the first several infusion cycles. Maintenance treatment with IVIG every three weeks has been shown to be effective over at least a year, with modeling suggesting that more frequent dosing provides more stable IgG levels.19PubMed Central. Intravenous immunoglobulin for maintenance treatment of multifocal motor neuropathy: A multi‐center, open‐label, 52‐week phase 3 trial20Frontiers in Neurology. Dose, exposure, and treatment regimen of intravenous immunoglobulin G in multifocal motor neuropathy
For inflammatory myositis, a related group of autoimmune muscle diseases, the timeline is slower still. A pilot study of treatment-naive myositis patients found that about 45 percent showed meaningful clinical improvement after six to nine weeks of IVIG as first-line therapy.21PubMed Central. Treatment with add-on IVIg in Myositis Early In the diSease course May be sUperior to Steroids alone for reaching CLinical improvEment (TIME IS MUSCLE): study protocol of a phase-2 double-blind placebo-controlled randomised trial Long-term conditions like stiff-person syndrome require ongoing maintenance IVIG, with about a quarter of responders sustaining benefit over a median of roughly 40 months, though nearly a third saw that benefit decline over a similar period.22PubMed Central. Long-term Effectiveness of IVIg Maintenance Therapy in 36 Patients With GAD Antibody-Positive Stiff-Person Syndrome
Primary Immunodeficiency: A Different Kind of Timeline
For people whose immune systems don’t produce enough antibodies on their own, IVIG isn’t treating an acute attack. It’s replacing what the body can’t make. The timeline here isn’t about “how fast will I feel better” so much as “how long until my IgG levels are where they need to be.”
With an aggressive loading schedule, target IgG levels above 5 g/L can be reached within the first week of therapy. Without loading, weekly subcutaneous injections bring levels up gradually over three to four weeks, and it takes roughly six months to reach a true steady state.23Clinical and Experimental Immunology. Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease In practical terms, patients often notice fewer infections within the first couple of months, but the full protective effect builds over time as trough levels stabilize.
The Wear-Off Effect
One of the more frustrating aspects of IVIG therapy is the wear-off phenomenon: patients feel worse toward the end of their dosing cycle as IgG levels drop. This has been documented across conditions but is perhaps best studied in primary immunodeficiency.
In a study tracking patient-reported well-being throughout dosing cycles, scores climbed in the first week or two after infusion, stayed stable briefly, and then fell steadily in the final week. The drop was consistent regardless of whether patients were on three-week or four-week cycles, with average well-being scores falling by about 1.2 points from peak to end-of-cycle. About 61 percent of patients on a three-week cycle and 43 percent on a four-week cycle experienced at least one episode of noticeable wear-off.24PubMed Central. Quantitative Evidence of Wear-Off Effect at the End of the Intravenous IgG (IVIG) Dosing Cycle in Primary Immunodeficiency The experience feels like a return of fatigue, increased susceptibility to infections, or worsening of condition-specific symptoms. Shortening the interval between infusions or switching to more frequent subcutaneous dosing are common strategies for managing this.
How Long the Infusion Itself Takes
Before IVIG can start working, it has to get into your bloodstream, and this step alone takes hours. Infusion protocols typically start at slow rates and escalate gradually, increasing every 15 to 30 minutes if no adverse reactions occur.25PubMed Central. IVIG Administration: Lessons from Cross-Institutional Protocol Review Maximum infusion rates vary widely between institutions and depend on the patient’s risk profile; those with kidney impairment or older adults are often kept at slower maximum rates.
For a typical adult dose, a single infusion session can last anywhere from two to six hours. Newer 10 percent IVIG formulations with faster escalation protocols have helped shorten infusion times at some centers.26PubMed Central. Reduction of Infusion Time Using a 10% Intravenous Immunoglobulin Formulation With a 15-Minute Rate Escalation Protocol During Staffing Shortages Due to COVID-19 For conditions requiring the standard high dose of 2 g/kg, treatment is usually split over two to five consecutive days, so the total loading course itself takes up much of the first week.
Most infusion-related side effects, such as headache, chills, and nausea, occur within the first hour of treatment and resolve within several hours. Delayed reactions, which are less common but more serious, can appear anywhere from six hours to a week afterward.27PubMed Central. Intravenous Immunoglobulin-Induced Aseptic Meningitis—A Narrative Review of the Diagnostic Process, Pathogenesis, Preventative Measures and Treatment
IVIG in Pregnancy and Reproductive Immunology
IVIG has found a growing role in two distinct reproductive scenarios: preventing fetal platelet destruction in alloimmune thrombocytopenia and supporting pregnancies in women with recurrent pregnancy loss. The timelines here are unique because the treatment is given preventively over weeks or months rather than to achieve a rapid clinical turnaround.
For fetal and neonatal alloimmune thrombocytopenia, mothers receive weekly IVIG infusions starting as early as 18 to 24 weeks of pregnancy and continuing until delivery. In a large study, about 83 percent of treated pregnancies showed a good response, with median platelet counts at birth of around 172,000/µL, well within the safe range.28Ultrasound in Obstetrics & Gynecology. Effectiveness of antenatal intravenous immunoglobulin treatment in recurrent fetal and neonatal alloimmune thrombocytopenia Because fetal platelet counts are not monitored during treatment, the effectiveness is only confirmed at delivery.
In recurrent pregnancy loss associated with abnormal immune markers, the timing of when IVIG is started appears to be critical. A propensity-matched cohort study found that starting IVIG between six and 12 weeks of gestation was associated with a live birth rate of about 73 percent, compared to roughly 45 percent in untreated controls, roughly a threefold improvement in odds.29Frontiers in Immunology. Early intravenous immunoglobulin use improves live birth outcomes in women with recurrent pregnancy loss: a propensity score–matched cohort study For women undergoing IVF with recurrent implantation failure, a meta-analysis found that IVIG treatment was associated with substantially higher clinical pregnancy and live birth rates in selected populations.30PubMed. Effect of intravenous immunoglobulin therapy in recurrent implantation failure: A Systematic review and meta-analysis These are not quick-turnaround applications. The treatment is sustained throughout much of the pregnancy, and the “result” is the outcome at delivery.
Why Response Speed Varies So Much Between People
Even within a single condition, two patients can receive the same IVIG dose and respond on very different timescales. Part of this comes down to how quickly each person’s body processes IgG. The half-life of infused IgG varies enormously: in one study of patients with chronic nerve diseases, it ranged from 11 to 60 days, with a median of about 23 days.3PubMed. Pharmacokinetics and Pharmacodynamics of Intravenous Immunoglobulin G Maintenance Therapy in Chronic Immune-mediated Neuropathies A patient at the short end of that range clears the drug nearly six times faster than one at the long end, which directly affects how high the levels stay and for how long.
The severity and stage of the underlying disease also play a role. In CIDP, patients with more severe baseline disability were the ones who showed the fastest measurable improvement, likely because there was more reversible nerve dysfunction to recover from.13JAMA Neurology. Timing and Course of Clinical Response to Intravenous Immunoglobulin in Chronic Inflammatory Demyelinating Polyradiculoneuropathy In GBS, the amount of IgG that remained in the blood two weeks after treatment, rather than the peak level right after infusion, was the strongest predictor of recovery.11PubMed Central. IVIG Treatment and Prognosis in Guillain–Barré Syndrome Body weight, baseline IgG levels, kidney function, and whether the patient has conditions that increase IgG catabolism all influence how much of the infused dose sticks around long enough to do its job.
For Kawasaki disease in particular, a constellation of inflammatory markers measured before and after treatment helps predict who will resist the standard dose. Elevated liver enzymes, higher inflammatory protein levels, and certain composite blood-count indices have all been linked to IVIG resistance across multiple large studies.8PubMed Central. Factors Predicting Resistance to Intravenous Immunoglobulin Treatment and Coronary Artery Lesion in Patients with Kawasaki Disease: Analysis of the Korean Nationwide Multicenter Survey from 2012 to 201431Frontiers in Immunology. Novel predictors of intravenous immunoglobulin resistance in patients with Kawasaki disease: a retrospective study The ability to identify these patients early is one of the more active areas of research, because the children who don’t respond to IVIG are the same ones at highest risk for coronary damage.